Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Search
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Our People, Our Culture
Our People, Our Culture
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
New GPP Consensus Statement Released
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Cares Product Donations Program
Boehringer Ingelheim Cares Product Donations Program
Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures
Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Skin and Inflammatory Diseases
skin diseases
PetPro Connect: Veterinary Medicine in the Digital Age
Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.
Fremont, CA site
Fremont, CA site
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Investigating MDM2-p53 in cancer
Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Citizen Petition
Citizen Petition
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Brigitte Fuhr
Our data transformation
Sites Around the World
Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.
Creating an Inclusive Workplace for Employees with Disabilities
Creating an Inclusive Workplace for Employees with Disabilities